Rosalind Advisors Inc. Grows Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Rosalind Advisors Inc. boosted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 18.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 885,000 shares of the biopharmaceutical company's stock after buying an additional 135,000 shares during the period. Ocular Therapeutix makes up about 4.8% of Rosalind Advisors Inc.'s holdings, making the stock its 10th largest holding. Rosalind Advisors Inc. owned 0.57% of Ocular Therapeutix worth $7,700,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in OCUL. Avoro Capital Advisors LLC purchased a new stake in shares of Ocular Therapeutix during the 1st quarter valued at $65,055,000. Assenagon Asset Management S.A. bought a new stake in Ocular Therapeutix during the third quarter worth about $24,584,000. Point72 Asset Management L.P. bought a new stake in Ocular Therapeutix during the second quarter worth about $18,514,000. Vanguard Group Inc. increased its position in shares of Ocular Therapeutix by 41.4% during the 1st quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company's stock valued at $65,840,000 after purchasing an additional 2,117,029 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new position in shares of Ocular Therapeutix during the 2nd quarter valued at about $6,840,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on OCUL shares. Robert W. Baird cut their target price on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Thursday, August 8th. Scotiabank assumed coverage on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $14.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, Ocular Therapeutix has a consensus rating of "Moderate Buy" and a consensus target price of $16.57.

Ocular Therapeutix Trading Up 3.5 %

NASDAQ:OCUL traded up $0.37 during midday trading on Wednesday, reaching $10.94. 1,016,736 shares of the stock traded hands, compared to its average volume of 1,889,850. The stock has a market capitalization of $1.71 billion, a P/E ratio of -8.10 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 16.55 and a current ratio of 16.64. The company has a fifty day moving average of $9.61 and a 200 day moving average of $7.74. Ocular Therapeutix, Inc. has a 12 month low of $2.00 and a 12 month high of $11.77.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.04). Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The firm had revenue of $16.40 million for the quarter, compared to the consensus estimate of $15.85 million. During the same period last year, the company posted ($0.27) earnings per share. The business's revenue was up 7.9% on a year-over-year basis. On average, research analysts predict that Ocular Therapeutix, Inc. will post -1.02 EPS for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.